Translationale experimentelle Publikationen


  • Haralambiev L, Nitsch A, Einenkel R, Muzzio DO, Gelbrich N, Burchardt M, Zygmunt M, Ekkernkamp A, Stope MB, Gümbel D (2020) The effect of cold atmospheric plasma on the membrane permeability of human osteosarcoma cells. Anticancer Res 40:841-846
  • Brünnert D, Langer C, Zimmermann L, Bargou RC, Burchardt M, Chatterjee M, Stope MB (2020) The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90β and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth. J Cell Biochem 121:407-417
  • Haralambiev L, Wien L, Gelbrich N, Lange J, Bakir S, Kramer A, Burchardt M, Ekkernkamp A, Gümbel D, Stope MB (2020) Cold atmospheric plasma inhibits the growth of osteosarcoma cells by induction of apoptosis, independent of the device used. Oncol Lett 19:283-290
  • Haralambiev L, Nitsch A, Jacoby JM, Strakeljahn S, Bekeschus S, Mustea A, Ekkernkamp A, Stope MB (2020) Cold atmospheric plasma treatment of chondrosarcoma cells affects proliferation and cell membrane permeability. Int J Mol Sci 21:2291
  • Daragan G, Hoffmann J,Vasko T, Mustea A, Burchardt M, Kraus T, Stope MB*, Ziegler P* (2019) Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenyls. Invest New Drugs 38:541–545
  • Kletschkus K, Haralambiev L, Nitsch A, Pfister F, Klinkmann G, Kramer A, Bekeschus S, Mustea A, Stope MB (2020) The application of a low-temperature physical plasma device operating under atmospheric pressure leads to the production of toxic NO2. Anticancer Res 40:2591-2599
  • Bekeschus S, Ressel V, Freund E, Gelbrich N, Mustea A, Stope MB (2020) Gas plasma-treated prostate cancer cells augment myeloid cell activity and cytotoxicity. Antioxidants 9:323
  • Klümper N, Ralser DJ, Bawden EG, Landsberg J, Zarbl R, Kristiansen G, Toma M,  Ritter M, Hölzel M, Ellinger J, Dietrich D (2020) LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cellcarcinoma. J Immunother Cancer 8:e000552
  • Feil L, Koch A, Utz R, Ackermann M, Barz J, Stope MB, Krämer B, Wallwiener D, Brucker SY, Weiss M (2020) Cancer-selective treatment of cancerous and non-cancerous human cervical cell models by a non-thermally operated electrosurgical argon plasma device. Cancers 12:1037


  • Weiss M, Barz J, Ackermann M, Utz R, Ghoul A, Weltmann KD, Stope MB, Wallwiener D, Schenke-Layland K, Oehr C, Brucker S, Loskill P (2019) Dose-dependent tissue-level characterization of a medical atmospheric pressure argon plasma jet. ACS Appl Mater Interfaces 11:19841-19853
  • Stope MB, Weiss M, Popp SL, Joffroy C, Buck MB, Mustea A, Brucker S, Wallwiener D, Knabbe C (2019) The pleiotropic factor Y-box binding protein-1 enhances the anti-proliferative efficacy of 4-hydroxytamoxifen and fulvestrant on breast cancer cells in vitro. Eur J Gynaecol Oncol 40:16-18
  • Ralser DJ, Takeuchi H, Fritz G, Basmanav FB, Effern M, Sivalingam S, El-Shabrawi-Caelen L, Degirmentepe EN, Kocatürk E, Singh M, Booken N, Spierings NMK, Schnabel V, Heineke A, Knuever J, Wolf S, Wehner M, Tronnier M, Leverkus M, Tantcheva-Poor I, Wenzel J, Oji V, Has C, Hölzel M, Frank J, Haltiwanger RS, Betz RC (2019) Altered notch signaling in Dowling-Degos disease: Additional mutations in POGLUT1 and further insights into disease pathogenesis. J Invest Dermatol 139:960-964
  • Reuter A, Sckell A, Brandenburg LO, Burchardt M, Kramer A, Stope MB (2019) Overexpression of microRNA-1 in prostate cancer cells modulates the blood vessel system of an in vivo Hen's Egg Test-Chorioallantoic Membrane model. In Vivo 33:41-46
  • Holstein S, Venz S, Junker H, Walther R, Stope MB, Zimmermann U (2019) Nicotinamide N-methyltransferase and its precursor substrate methionine directly and indirectly control malignant metabolism during progresssion of renal cell carcinoma. Anticancer Res 39:5427-5436
  • Knuever J, Persa OD, Illerhaus A, Ralser DJ, Hartmann K, Betz RC, Tantcheva-Poor I (2019): Mast cell activation in Dowling-Degos disease. Br J Dermatol 181:1312-1314
  • Bekeschus S, Schütz C, Nießner F, Wende K, Weltmann KD, Gelbrich N, Woedtke T, Schmidt A, Stope MB (2019) Elevated H2AX phosphorylation observed with kINPen plasma treatment is not caused by ROS-mediated DNA damage but is the consequence of apoptosis. Oxid Med Cell Longev 2019:8535163
  • Nitsch A, Haralambiev L, Einenkel R, Muzzio DO, Zygmunt MT, Ekkernkamp A, Burchardt M, Stope MB (2019) Determination of in vitro membrane permeability by analysis of intracellular and extracellular fluorescein signals in renal cells. In Vivo 33:1767-1771
  • Freund E, Moritz J, Stope MB, Seebauer C, Schmidt A, Bekeschus S (2019) Plasma-derived reactive species shape a differentiation profile in human monocytes. Appl Sci 9:2530
  • Abazid A, Martin B, Choinowski A, McNeill RV, Brandenburg LO, Ziegler P, Zimmermann U, Burchardt M, Erb H, Stope MB (2019) The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells. J Cell Biochem 120:16711-16722
  • Ahrend H, Daeschlein G, Grove E, Paditz M, Mustea A, Burchardt M, Stope MB (2019) MicroRNA-20a-3p and microRNA-20a-5p exhibit anti-proliferative activities in a melanoma in vitro model. SDRP Journal of Cellular and Molecular Physiology 3:1-7
  • Rottach AM, Ahrend H, Martin B, Walther R, Zimmermann U, Burchardt M, Stope MB (2019) Cabazitaxel inhibits prostate cancer cell growth by inhibition of androgen receptor and heat shock protein expression. World J Urol 37:2137–2145
  • Haralambiev L, Wien L, Gelbrich N, Kramer A, Mustea A, Burchardt M, Ekkernkamp A, Stope MB, Gümbel D (2019) Effects of cold atmospheric plasma on the expression of chemokines, growth factors, TNF superfamily members, interleukins, and cytokines in human osteosarcoma cells. Anticancer Res 39:151-157
  • Gelbrich N, Nitsch A, Burchardt M, Stope MB (2019) Kaltes atmosphärisches Plasma - Antineoplastische Effekte auf Nierenzellkarzinom-Zellen. Urologische Nachrichten 09/2019:5